Marc Belsky

Marc Belsky is a declared insider at 3 companies; the most frequent names are Five Prime Therapeutics Inc, Kezar Life Sciences, Inc. and Cell Genesys Inc. The record holds 35 filings, for trades running from 30 July 2007 to 4 February 2020.

On the open market, the record shows 6 purchases worth €44k and 5 sales worth €2.8M. Netting one side against the other leaves €2.8M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 13 share grants and 10 option exercises. 2020 to date brings 1 purchase and no sales.

The median purchase comes to €2,080. Clusters matter here: 5 out of 6 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 5 February 2020, reports an open-market purchase of €36k in Kezar Life Sciences, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.